Is it okay to use a commercially available AST for Burkholderia cepacia complex?
Journal of Clinical Microbiology · 10.06.2026 · 64 (6)
DOI: 10.1128/jcm.01871-25 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of Clinical Microbiology, erschienen am 10.06.2026. Verfasst von April M Bobenchik und 1 weiteren Autor:innen. Beteiligte Einrichtung: Penn State Hershey Medical Center and College of Medicine, Hershey, Pennsylvania, USA. Hauptthemen laut MEDLINE: Burkholderia cepacia complex, Anti-Bacterial Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In the article published by K. L. Shier, G. Gonzales, D. A. G. Perez, J. R. Bao, et al. (J Clin Microbiol 64:e00484-25, 2026, https://www.doi.org/10.1128/jcm.00484-25 ), the authors evaluated the performance of the Vitek 2 (bioMérieux), Sensititre (Thermo Fisher), and Etest (bioMérieux) Antimicrobial Susceptibility Testing (AST) methods compared to reference broth microdilution for 46 reference Burkholderia cepacia complex (BCC) isolates. This study reports on several of the most widely used commercial AST systems across laboratory settings, including commercial reference laboratories, and concludes that Sensititre may be a viable commercial option when susceptibility testing is warranted. Here, we review the reproducibility and performance characteristics of various AST methods for BCC, highlight the challenges of performing AST, and discuss the future of susceptibility testing for this organism group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Penn State Hershey Medical Center and College of Medicine, Hershey, Pennsylvania, USA.
- Quest Diagnostics, Clifton, New Jersey, USA.
ORCID-Profile: April M Bobenchik
Zitieren
APA
Bobenchik, A. M., & Uprety, P. (2026). Is it okay to use a commercially available AST for Burkholderia cepacia complex?. Journal of Clinical Microbiology, 64(6). https://doi.org/10.1128/jcm.01871-25
Vancouver
Bobenchik AM, Uprety P. Is it okay to use a commercially available AST for Burkholderia cepacia complex?. Journal of Clinical Microbiology. 2026;64(6). doi:10.1128/jcm.01871-25
BibTeX
@article{Bobenchik2026,
author = {Bobenchik, April M and Uprety, Priyanka},
title = {Is it okay to use a commercially available AST for Burkholderia cepacia complex?},
journal = {Journal of Clinical Microbiology},
year = {2026},
volume = {64},
number = {6},
doi = {10.1128/jcm.01871-25}
}
EUVIMED